{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:31:22Z","timestamp":1776382282062,"version":"3.51.2"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004462","name":"Consiglio Nazionale delle Ricerche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007387","name":"Fondazione Cassa di Risparmio di Pistoia e Pescia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejmech.2021.113260","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T01:50:26Z","timestamp":1612489826000},"page":"113260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II"],"prefix":"10.1016","volume":"214","author":[{"given":"Elena","family":"Lenci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Calugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-7504","authenticated-orcid":false,"given":"Riccardo","family":"Innocenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Carta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1774-9301","authenticated-orcid":false,"given":"Andrea","family":"Trabocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113260_bib1a","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","article-title":"Carbonic anhydrase: chemistry, physiology, and inhibition","volume":"47","author":"Maren","year":"1967","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113260_bib1b","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"13","key":"10.1016\/j.ejmech.2021.113260_bib1c","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1016\/j.bmc.2007.04.020","article-title":"Carbonic anhydrases as targets for medicinal chemistry","volume":"15","author":"Supuran","year":"2007","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib2a","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/138161207779313551","article-title":"Matrix metalloproteinases as valid clinical targets","volume":"13","author":"Fingleton","year":"2007","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2021.113260_bib2b","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.mam.2008.05.002","article-title":"Progress in matrix metalloproteinase research","volume":"29","author":"Murphy","year":"2008","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.ejmech.2021.113260_bib2c","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cells8090984","article-title":"The rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma","volume":"8","author":"Fields","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2021.113260_bib3a","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/med.10025","article-title":"Carbonic anhydrase inhibitors","volume":"23","author":"Supuran","year":"2003","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113260_bib3b","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/138161208783877884","article-title":"Carbonic anhydrases--an overview","volume":"14","author":"Supuran","year":"2008","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2021.113260_bib3c","series-title":"Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications","first-page":"15","article-title":"Carbonic anhydrases as drug targets \u2013 general presentation","author":"Supuran","year":"2009"},{"key":"10.1016\/j.ejmech.2021.113260_bib4a","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.02.005","article-title":"Biochemical and biological attributes of matrix metalloproteinases","volume":"147","author":"Cui","year":"2017","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.ejmech.2021.113260_bib4b","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2174\/1568026043387368","article-title":"A\u00a0bioinorganic perspective on matrix metalloproteinase inhibition","volume":"4","author":"Puerta","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib4c","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.2741\/2024","article-title":"Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions","volume":"11","author":"Varghese","year":"2006","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2021.113260_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2021.113260_bib6a","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113260_bib6b","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3389\/fimmu.2019.01278","article-title":"Mechanisms of action of novel drugs targeting angiogenesis-promoting matrix metalloproteinases","volume":"10","author":"Fields","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ejmech.2021.113260_bib6c","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.biochi.2004.12.009","article-title":"Collagenases in cancer","volume":"87","author":"Ala-aho","year":"2005","journal-title":"Biochimie"},{"issue":"33","key":"10.1016\/j.ejmech.2021.113260_bib7a","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.2174\/0929867325666180607094856","article-title":"Dual inhibitors as a New challenge for cancer multidrug resistance treatment","volume":"26","author":"Stankovi\u0107","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2021.113260_bib7b","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.ejmech.2021.113260_bib7c","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2021.113260_bib7d","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tips.2004.12.002","article-title":"Overcoming limitations of natural anticancer drugs by combining with artificial agents","volume":"26","author":"Blagosklonny","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2021.113260_bib8a","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165737","article-title":"The human kinome targeted by FDA approved multi-target drugs and combination products: a comparative study from the drug-target interaction network perspective","volume":"11","author":"Li","year":"2016","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113260_bib8b","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","article-title":"Dual inhibitors of human DNA topoisomerase II and other cancer-related targets","volume":"63","author":"Skok","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib8c","doi-asserted-by":"crossref","first-page":"111541","DOI":"10.1016\/j.ejmech.2019.07.044","article-title":"Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis","volume":"181","author":"Huang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib9a","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.bmcl.2014.04.077","article-title":"Dual carbonic anhydrase\/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors","volume":"24","author":"Tauro","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113260_bib9b","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1016\/j.bmcl.2010.04.109","article-title":"New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors, Bioorg","volume":"20","author":"Esteves","year":"2010","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113260_bib9c","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1021\/jm000027t","article-title":"Carbonic anhydrase and matrix metalloproteinase Inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes","volume":"43","author":"Scozzafava","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib9d","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1021\/jm300981b","article-title":"Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment","volume":"55","author":"Reich","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib10a","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbamcr.2009.04.010","article-title":"Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition?","volume":"1803","author":"Sela-Passwell","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2021.113260_bib10b","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10555-014-9530-4","article-title":"New approaches to selectively target cancer-associated matrix metalloproteinase activity","volume":"33","author":"Tauro","year":"2014","journal-title":"Canc. Metastasis Rev."},{"key":"10.1016\/j.ejmech.2021.113260_bib10c","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.2174\/092986709789178037","article-title":"Selective matrix metallo proteinase inhibitors for cancer","volume":"16","author":"Lia","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/35036374","article-title":"Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis","volume":"2","author":"Bergers","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113260_bib12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1055\/s-0037-1615367","article-title":"Localization and translocation of MMP-2 during aggregation of human platelets","volume":"80","author":"Sawicki","year":"1998","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2021.113260_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1126\/science.277.5323.225","article-title":"Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5","volume":"277","author":"Giannelli","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.113260_bib14a","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/1568009053765799","article-title":"Matrix metalloproteinases as therapeutic targets in cancer","volume":"5","author":"Vihinen","year":"2005","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2021.113260_bib14b","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1517\/14728222.7.3.385","article-title":"Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects","volume":"7","author":"Fingleton","year":"2003","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2021.113260_bib14c","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/35081571","article-title":"Metalloproteinases in biology and pathology of the nervous system","volume":"2","author":"Yong","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113260_bib14d","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1517\/13543784.9.5.993","article-title":"Ongoing trials with matrix metalloproteinase inhibitors","volume":"9","author":"George","year":"2000","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2021.113260_bib15","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4155\/fmc.11.69","article-title":"Carbonic anhydrase inhibitors and activators for novel therapeutic applications","volume":"3","author":"Supuran","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib16","first-page":"998","article-title":"Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer","volume":"47","author":"Bekku","year":"2000","journal-title":"Hepato-Gastroenterology"},{"issue":"6","key":"10.1016\/j.ejmech.2021.113260_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1747-0285.2011.01104.x","article-title":"Vitro inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds","volume":"77","author":"Senturk","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"issue":"5","key":"10.1016\/j.ejmech.2021.113260_bib18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/modpathol.2009.189","article-title":"Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors","volume":"23","author":"Parkkila","year":"2010","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.ejmech.2021.113260_bib19","first-page":"6495","article-title":"Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumor","volume":"8","author":"Liu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"20","key":"10.1016\/j.ejmech.2021.113260_bib20a","doi-asserted-by":"crossref","first-page":"127467","DOI":"10.1016\/j.bmcl.2020.127467","article-title":"Discovery of a D-pro-lys peptidomimetic inhibitor of MMP9: addressing the gelatinase selectivity beyond S1\u2032 subsite","volume":"30","author":"Lenci","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"9","key":"10.1016\/j.ejmech.2021.113260_bib20b","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.bmc.2019.03.043","article-title":"Identification of highly potent and selective MMP2 inhibitors addressing the S1\u2032 subsite with D-proline-based compounds","volume":"27","author":"Lenci","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib20c","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1039\/C4MD00287C","article-title":"A\u00a0study of a d-proline peptidomimeticinhibitor of melanoma and endothelial cell invasion through activity towards MMP-2 and MMP-9","volume":"6","author":"Bianchini","year":"2015","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.ejmech.2021.113260_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2012.08.028","article-title":"D-Proline-based peptidomimetic inhibitors of anthrax lethal factor","volume":"56","author":"Calugi","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib22a","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1021\/jm0501073","article-title":"Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors","volume":"48","author":"Cecchi","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib22b","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1021\/jm031079w","article-title":"Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX","volume":"47","author":"Casey","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2021.113260_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bmc.2008.11.010","article-title":"Novel chemotactic For-Met-Leu-Phe-OMe (fMLF-OMe) analogues based on Met residue replacement by 4-amino-proline scaffold: synthesis and bioactivity","volume":"17","author":"Torino","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/oncotarget.422","article-title":"Recent developments in targeting carbonic anhydrase IX for cancer therapeutics","volume":"3","author":"McDonald","year":"2012","journal-title":"Oncotarget"},{"issue":"47","key":"10.1016\/j.ejmech.2021.113260_bib25","doi-asserted-by":"crossref","first-page":"83088","DOI":"10.18632\/oncotarget.20236","article-title":"Overexpression of carbonic anhydrase IX induces cell motility by activating matrix metalloproteinase-9 in human oral squamous cell carcinoma cells","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.ejmech.2021.113260_bib26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.4065\/82.7.878","article-title":"Oral cancer","volume":"82","author":"Mayo","year":"2007","journal-title":"Clin Proc"},{"key":"10.1016\/j.ejmech.2021.113260_bib27","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase","volume":"246","author":"Khalifah","year":"1971","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib28a","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1016\/j.bmc.2017.05.014","article-title":"Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors","volume":"25","author":"Angeli","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib28b","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejmech.2018.05.026","article-title":"Design, synthesis and X-ray crystallography of selenides bearing benzenesulfonamide moiety with neuropathic pain modulating effects","volume":"154","author":"Angeli","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib28c","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/cmdc.201700446","article-title":"Sulfocoumarin-,Coumarin-, 4-sulfamoylphenyl-bearing indazole-3-carboxamide hybrids: synthesis and selective inhibition of tumor-associated carbonic anhydrase isozymes IX and XII","volume":"12","author":"Angapelly","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113260_bib29","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2021.113260_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.str.2005.01.009","article-title":"Tangible interfaces for structural molecular biology","volume":"13","author":"Gillet","year":"2005","journal-title":"Structure"},{"issue":"3","key":"10.1016\/j.ejmech.2021.113260_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/B:JCAM.0000035186.90683.f2","article-title":"VEGA--an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming","volume":"18","author":"Pedretti","year":"2004","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2021.113260_bib32","unstructured":"W. L. DeLano, \u2018The PyMOL Molecular Graphics System.\u2019 DeLano Scientific LLC, San Carlos, CA, USA ([http:\/\/www.pymol.org])."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:23:21Z","timestamp":1759328601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":60,"alternative-id":["S0223523421001094"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113260","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113260"}}